• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Harmony Biosciences Holdings Inc.

    4/4/25 4:19:05 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HRMY alert in real time by email
    DEFA14A 1 ny20043375x2_defa14a.htm DEFA14A
     
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 14A
    PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE
    SECURITIES EXCHANGE ACT OF 1934
     
    Filed by the Registrant ☒
    ​ ​
    Filed by a Party other than the Registrant  ☐
    Check the appropriate box:
     ☐
    Preliminary Proxy Statement
     ☐
    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐
    Definitive Proxy Statement
    ☒
    Definitive Additional Materials
     ☐
    Soliciting Material Pursuant to  ☐ 240.14a-11(c) or  ☐ 240.14a-2
    Harmony Biosciences Holdings, Inc.
    (Name of Registrant as Specified In Its Charter)
    Payment of Filing Fee (Check the appropriate box):
    ☒
    ​ ​
    No fee required.
    ☐    
    Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
     ☐
    ​ ​
    Fee paid previously with preliminary materials.
     ☐
    ​ ​
    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
     
     



    Get the next $HRMY alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HRMY

    DatePrice TargetRatingAnalyst
    7/21/2025$48.00Buy
    Truist
    7/10/2025$33.00Neutral
    Goldman
    6/2/2025$61.00Outperform
    Oppenheimer
    2/11/2025$55.00Buy
    Deutsche Bank
    12/17/2024$75.00Buy
    H.C. Wainwright
    10/10/2024Outperform
    Raymond James
    9/10/2024$56.00Buy
    UBS
    6/21/2024$48.00Buy
    Citigroup
    More analyst ratings

    $HRMY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on Harmony Biosciences with a new price target

    Truist initiated coverage of Harmony Biosciences with a rating of Buy and set a new price target of $48.00

    7/21/25 8:34:40 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman resumed coverage on Harmony Biosciences with a new price target

    Goldman resumed coverage of Harmony Biosciences with a rating of Neutral and set a new price target of $33.00

    7/10/25 8:55:45 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer resumed coverage on Harmony Biosciences with a new price target

    Oppenheimer resumed coverage of Harmony Biosciences with a rating of Outperform and set a new price target of $61.00

    6/2/25 8:52:53 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRMY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Harmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025

    WAKIX® (pitolisant) Franchise Continues Strong Growth with Net Revenue of $200.5M for Q2 2025 (+16% YoY Growth); Increases Average Patients by 400 to Achieve 7,600 Average Patients in Q2 2025 Phase 3 RECONNECT Study in Fragile X Syndrome (FXS) Designed to Confirm Positive Findings from the Phase 2/3 CONNECT Study; Opportunity to Address Unmet Needs of 80,000 Patients with FXS On Track to Begin First-in-Human Clinical Trial with BP1.15205, a Potential Best-In-Class Orexin-2 Agonist, in 2H 2025 Initiation of Next-Generation Pitolisant HD Phase 3 Registrational Trials in Narcolepsy & Idiopathic Hypersomnia in Q4 2025; Both Indications Targeted for PDUFA in 2028 Conference Call

    8/5/25 7:30:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025

    Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that it will report second quarter 2025 financial results on Tuesday, August 5, 2025, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on August 5, 2025, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial 833-316-2483 (domestic) or 785-838-9284 (international), and reference passcode HRMYQ225. It is recommended that you dial in at least 10 minutes prior to the call. The live and replay webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/. About Harmony Biosciences Harmony Biosciences is

    7/22/25 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harmony Biosciences to Participate in H.C. Wainwright "HCW@Home" Series

    Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced that Harmony's management team will participate in the virtual H.C. Wainwright "HCW@Home" series on Thursday, July 17, 2025, at 10:00 a.m. ET. To register in advance, please use this link. A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences website at https://ir.harmonybiosciences.com/. About Harmony Biosciences Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel ov

    7/15/25 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRMY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Sabater Juan A.

    4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)

    5/16/25 4:05:59 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Gracias Antonio J.

    4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)

    5/16/25 4:05:30 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Philip Ron M

    4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)

    5/16/25 4:04:33 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRMY
    SEC Filings

    View All

    SEC Form 144 filed by Harmony Biosciences Holdings Inc.

    144 - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)

    8/15/25 4:28:30 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Harmony Biosciences Holdings Inc.

    10-Q - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)

    8/5/25 8:16:04 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harmony Biosciences Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)

    8/5/25 8:00:19 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRMY
    Leadership Updates

    Live Leadership Updates

    View All

    Harmony Biosciences Appoints Biotech Leader Ron Philip to Its Board of Directors

    Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced the appointment of Ron Philip to the Company's Board of Directors. Ron Philip is the President and Chief Executive Officer of Orbital Therapeutics. Ron has 30 years of experience building companies, leading organizational growth, and guiding teams through the development, regulatory approval, and commercialization of novel therapies. Prior to Orbital, he was Chief Executive Officer of Spark Therapeutics, where he led the commercial launch of a novel gene therapy to treat an inherited form of blindness, expanded its therapeutic platform to larger disease areas, and acquired new technologies and assets through business developm

    4/3/25 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harmony Biosciences Names Adam Zaeske as Chief Commercial Officer to Lead the Next Phase of Commercial Growth as Its Portfolio Expands

    Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced the appointment of Adam Zaeske as Executive Vice President and Chief Commercial Officer (CCO), effective March 31, 2025. The company's current CCO, Jeffrey Dierks, is voluntarily stepping down for personal reasons. Zaeske brings 25 years of global leadership across the pharmaceutical industry, building teams and transforming organizations in both the U.S. and Europe. He has broad functional experience spanning commercial strategy and operations, sales, marketing, market access, new product planning and finance. At Harmony, Zaeske will be responsible for leading the company's commercial organization, setting commercial strate

    3/24/25 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HARMONY BIOSCIENCES APPOINTS JEFFREY M. DAYNO, MD AS INTERIM CEO AND EXPANDS ROLE OF JEFF ARONIN TO EXECUTIVE CHAIRMAN

    PLYMOUTH MEETING, Pa., Jan. 6, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that John C. Jacobs is stepping down as President and Chief Executive Officer and a member of the Board of Directors to pursue another opportunity. The Harmony Board of Directors has named Jeffrey M. Dayno, MD, Harmony's Executive Vice President and Chief Medical Officer, as interim CEO effective immediately. Jeff Aronin, Harmony's founder and Board chairman, will continue to lead the Board of Directors as well as

    1/6/23 4:39:00 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRMY
    Financials

    Live finance-specific insights

    View All

    Harmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025

    WAKIX® (pitolisant) Franchise Continues Strong Growth with Net Revenue of $200.5M for Q2 2025 (+16% YoY Growth); Increases Average Patients by 400 to Achieve 7,600 Average Patients in Q2 2025 Phase 3 RECONNECT Study in Fragile X Syndrome (FXS) Designed to Confirm Positive Findings from the Phase 2/3 CONNECT Study; Opportunity to Address Unmet Needs of 80,000 Patients with FXS On Track to Begin First-in-Human Clinical Trial with BP1.15205, a Potential Best-In-Class Orexin-2 Agonist, in 2H 2025 Initiation of Next-Generation Pitolisant HD Phase 3 Registrational Trials in Narcolepsy & Idiopathic Hypersomnia in Q4 2025; Both Indications Targeted for PDUFA in 2028 Conference Call

    8/5/25 7:30:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025

    Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that it will report second quarter 2025 financial results on Tuesday, August 5, 2025, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on August 5, 2025, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial 833-316-2483 (domestic) or 785-838-9284 (international), and reference passcode HRMYQ225. It is recommended that you dial in at least 10 minutes prior to the call. The live and replay webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/. About Harmony Biosciences Harmony Biosciences is

    7/22/25 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harmony Biosciences Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance ​

    WAKIX® (pitolisant) Net Revenue of $184.7 Million for First Quarter 2025; Representing 20% Growth Year-over-Year; Reiterates Guidance of $820-$860M​ Net Income Grew 19% Year-over-Year, Building on Four Consecutive Years of Profitability; Increased Cash and Investments to Over $600 Million on Balance Sheet Completed Recruitment of Phase 3 Registrational Trial of ZYN002 in Fragile X Syndrome; On Track for Topline Data in Q3 BP1.15205, Potential Best in Class Orexin, Data to Be Presented at SLEEP 2025 Conference in June On Track for Initiation of Next-Generation Pitolisant-HD Phase 3 Registrational Trials in Narcolepsy & IH in Q4 ​Conference Call and Webcast to be Held Today at

    5/6/25 7:30:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRMY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Harmony Biosciences Holdings Inc. (Amendment)

    SC 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)

    2/13/24 7:06:51 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Harmony Biosciences Holdings Inc. (Amendment)

    SC 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)

    2/13/24 5:06:22 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Harmony Biosciences Holdings Inc. (Amendment)

    SC 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)

    2/9/24 9:03:03 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care